Slide 1: MedImmune: Delivering the next wave of scientific innovation
MedImmune Delivering the next wave of scientific innovation Bahija Jallal, Executive Vice President, MedImmune
Slide 2: Building on the fundamentals
Building on the fundamentals Next wave of science 1 – MedImmune
Slide 3: MedImmune has a 25+ year history in biologics; pioneering scientists still driving discoveries
MedImmune has a 25+ year history in biologics; pioneering scientists are still driving discoveries today RespiGam 1996 2002 Gail Wasserman, PhD Mike McCarthy, MD, MPH, MS Tris Vaughan, PhD 1998 Biopharmaceutical Dev. Infectious Diseases / Vaccines Antibody Discovery & Pennsylvania State Uni. U. Mary
Slide 4: MedImmune continues to attract world class scientists with strong expertise
MedImmune continues to attract world class scientists with strong expertise in areas of interest Yong-Jun Liu, MD, PhD Jack Ratchford, MD Head of Research Neuro-Immunology Baylor Research Institute Chief Scientific Johns Hopkins U. School of Medicine Officer and Director of Immunology Columbia U. Co
Slide 5: MedImmune has a collaborative work environment where staff are encouraged to publish & innovate
MedImmune has a collaborative work environment where staff are encouraged to publish & innovate 4 – MedImmune
Slide 6: Strength in immunology
Our sustainable pipeline is built on excellence in science Expertise in Strength Excellence in technology & in translational protein immunology research engineering 5 – MedImmune
Slide 7: MedImmune's strong heritage in immunology is leveraged across therapeutic areas
MedImmune’s strong heritage in immunology is leveraged across therapeutic areas Respiratory, inflammatory, Oncology: Immuno- autoimmune diseases oncology therapies Tempering overactive or Harnessing / activating the inappropriate immunity immune system Immune system Chronic inflammation Chronic infl
Slide 8: Disease biology drives our tech focus: novel non-mAb formats represent >50% of research portfolio
Disease biology drives our tech focus: Novel (non mAb) drug formats represent >50% of our research portfolio Deep “toolkit” of non-mAb …and growing as a proportion of the approaches… preclinical pipeline 60% Ab-drug Ab Bispecific conjugate mimetic Ab 50% Dual peptide 40% 30% mAb 20% (+YTE) Peptide m
Slide 9: Personalised healthcare is a core principle
Personalised healthcare is a core principle: More than 80% of our biologics portfolio employs a PHC approach Example: PD-L1 PD-L1 protein expression may not be an absolute determinant of response…we leverage multiple tools to identify responders Antibody and TCR diversity Circulating Genomics Flow c
Slide 10: Building on the fundamentals: Next wave of science
Building on the fundamentals Next wave of science 9 – MedImmune
Slide 11: Research & Early Development portfolio is robust with emphasis on core TAs
MedImmune’s Research & Early Development portfolio is robust with emphasis on core TAs Lead Optimisation Pre-clinical Phase I Phase IIa Phase IIb Onc RIA Onc MEDI3617 MEDI-551 MEDI2070/AMG-139 anifrolumab Ang2; GBM CD19; MS IL-23p19; Crohn’s IFNaR; SLE Onc RIA Onc MEDI-565 MEDI5872/AMG-557 tralokinu
Slide 12: Sjögren's programme employs the novel Tn3 scaffold to avoid mAb-related complications
MedImmune’s programme for Sjögren's employs the novel Tn3 scaffold to avoid mAb-related complications MEDI4920: Target • Blocks co-stimulatory path for CD40L on T cells to bind to CD40 on B cells Rationale • mAbs efficacious in animal models Platelet Aggregation • mAbs tested in the clinic with some
Slide 13: Novel ADC candidate employs the PBD payload and demonstrates early efficacy
MedImmune’s novel ADC candidate employs the PBD payload and demonstrates early efficacy against cancer ADC: Target H1975 NSCLC xenograft: Tumor regression with single dose ADC • Cancer stem cell target • Limited expression in normal tissues Indication • Overexpressed in several tumor types – Lung –
Slide 14: Building our early ADC pipeline; pursuing a broad range of oncology targets
We are building our early ADC pipeline; vigorously pursuing a broad range of oncology targets ADC research portfolio 2015 2016 2017 ADC1 IND ADC2 IND ADC3 IND ADC4 IND ADC5 IND ADC6 IND ADC7 IND ADC8 IND ADC9 IND • Forecast is subject to project attrition • Target discovery activities have launched
Slide 15: Next generation, extended half-life mAb for RSV
MedImmune is progressing a next generation, extended half-life mAb for RSV MEDI8897 : Target • Novel, neutralizing epitope on the RSV F protein, located on the surface of the virion Serum PK in NHP Model Indication • Passive immunization of all infants entering their 1st RSV season • Children with c
Slide 16: Multi-functional, bi-specific approach for the treatment of P. aeruginosa
MedImmune is pursuing an innovative multi-functional, bi-specific approach for the treatment of P. aeruginosa MEDI3902 : Target #1: PcrV – Virulence • Prevents toxin injection anti-PcrV into host cells anti-Psl • High affinity mAb to low density target Target #2: Psl – Colonisation Persistence • Dua
Slide 17: Protein X presents an opportunity to deliver a step change in diabetes therapy
Protein X presents an opportunity to deliver a step change in diabetes therapy Protein X: Target 18 16 • Novel protein with novel mechanism of Veh Glucose (mM) action 14 ** Low 12 * Indication 10 High *** *** 8 * ** • Type 2 Diabetes * *** 6 • Goal 0 10 20 30 – Dose-dependent reductions in blood sug
Slide 18: Summary
Summary We have created a vibrant environment, promoting innovation and scientific excellence We have a robust, balanced, sustainable portfolio We are moving beyond mAbs, pioneering the next wave of biologics innovation 17 – MedImmune
Slide 19: We push the boundaries of science to deliver life-changing medicines
We push the boundaries of science to deliver life-changing medicines 18 – MedImmune
Slide 20: Q&A
Q&A Briggs Morrison, moderator Mene Pangalos Bahija Jallal